ClinicalTrials.gg
Sign In
RecruitingNCT06383806DAWNUpdated Jul 15, 2026

Decreasing Nightmares in Adults With Narcolepsy

An interventional study of Imagery Rehearsal Therapy (IRT) in Narcolepsy, Narcolepsy Type 1 and Narcolepsy With Cataplexy, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by University of Utah · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with narcolepsy. All participants will receive the treatment and will complete three assessments. Half of the participants will receive the treatment after the first assessment, and half will receive it after the second assessment. Romantic partners of participants with narcolepsy will also be eligible to enroll in the study. Partners will complete three assessments but will not participate in the treatment.

02

Conditions studied

  • Narcolepsy
  • Narcolepsy Type 1
  • Narcolepsy With Cataplexy
  • Narcolepsy Without Cataplexy
  • Nightmare
  • Nightmare Disorder With Associated Other Sleep Disorder

Browse trials for

Keywords

  • Imagery Rehearsal Therapy
  • Cognitive Behavioral Therapy for Nightmares
03

In context

Narcolepsy

157 studies on the registry are indexed under Narcolepsy; 37 are open to participants now.

This study's planned enrollment of 80 is close to the median of 78 across 114 interventional studies indexed under Narcolepsy.

Browse Narcolepsy studies →

Lead sponsor

University of Utah is the lead sponsor of 994 studies on the registry; 175 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.

Browse University of Utah studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PARTICIPANTS WITH NARCOLEPSY/NIGHTMARES

Inclusion Criteria:

  • Diagnosis of narcolepsy type 1 or narcolepsy type 2
  • Nightmare frequency of ≥1 times per week
  • Age 18 or older
  • Able to speak, read, and write in English
  • Live in the United States
  • Sleep and psychiatric medications stable for ≥ 1 month and willing to keep medications stable for the duration of the study

Exclusion Criteria:

  • Currently engaged in trauma- or sleep-related psychotherapy
  • Previous behavioral treatment for nightmares
  • Medical, psychiatric, or cognitive condition which would interfere with ability to engage in the treatment
  • Untreated moderate-severe sleep apnea

PARTICIPANTS WHO ARE PARTNERS OF SOMEONE WITH NARCOLEPSY

Inclusion Criteria:

  • Live with a romantic partner who meets the above criteria and has agreed to participate in the study
  • Age 18 or older
  • Able to speak, read, and write in English
  • Live in the United States
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Treatment

    The Treatment arm will receive the intervention immediately following the first assessment.

    Behavioral: Imagery Rehearsal Therapy (IRT)

  • Other
    Waitlist

    The Waitlist arm will undergo a waiting period following the first assessment and then will receive the treatment after the second assessment.

    Behavioral: Imagery Rehearsal Therapy (IRT)

Interventions

  • BehavioralImagery Rehearsal Therapy (IRT)

    The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.

    Also known as: Cognitive Behavioral Therapy for Nightmares (CBT-N)

06

What researchers measure

Primary outcomes

  1. Disturbing Dream and Nightmare Severity Index (DDNSI)

    The DDNSI is a questionnaire which measures the severity of nightmares.

    Time frame: Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)

  2. Nightmare frequency (sleep diary)

    The number of nightmares experienced each day will be collected on daily sleep diaries completed during each assessment period.

    Time frame: Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)

Secondary outcomes

  1. PROMIS Anxiety

    Questionnaire which measures the severity of anxiety symptoms.

    Time frame: Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)

  2. PROMIS Depression

    Questionnaire which measures the severity of depressive symptoms.

    Time frame: Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2027, 14 months after the start.

Of 21 interventional studies with no phase under Narcolepsy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Jul 1, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06383806
Lead sponsor
University of Utah
Responsible party
Jennifer Mundt (Assistant Professor, University of Utah) — Principal investigator
First posted
Apr 25, 2024
Start date
Jul 1, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Jennifer Mundt, PhD
Contact
DAWNstudy@utah.edu
801-646-8287

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Narcolepsy →

Other studies from this sponsor

University of Utah →

Start the discussion